



Original Effective Date: 08/01/2017
Current Effective Date: 09/21/2025
Last P&T Approval/Version: 7/30/2025
Next Review Due By: 07/2026
Policy Number: C15389-A

Erythropoiesis-stimulating agents (ESAs)

PRODUCTS AFFECTED

Aranesp (darbepoetin alfa), Epogen (epoetin alfa), Mircera (methoxy polyethylene glycol-epoetin beta), Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

DIAGNOSIS:

Anemia associated with chronic kidney disease (CKD), including members on dialysis and members not on dialysis, Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy, Reduction of allogeneic blood transfusion in surgery, Anemia in HIV-infected members receiving zidovudine treatment, Anemia associated with myelodysplastic syndrome, Anemia of prematurity

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review. When the requested drug product for coverage is dosed by weight, body surface area or other member specific measurement, this data element is required as part of the medical necessity review. The Pharmacy and Therapeutics Committee has determined that the drug benefit shall be a mandatory generic and that generic drugs will be dispensed whenever available.

Drug and Biologic Coverage Criteria

A. FOR ALL INDICATIONS:

1. (a) Documentation of iron levels (dated within the last 60 days) with the following: Transferrin saturation equal to or greater than 20% AND serum ferritin equal to or greater than 100 ng/mL
OR
(b) Member is receiving appropriate iron supplementation
AND
2. Prescriber attests to (or the clinical reviewer has found that) the member not having any FDA labeled contraindications that haven't been addressed by the prescriber within the documentation submitted for review [Contraindications to erythropoiesis-stimulating agents (ESAs) include: uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with erythropoietin protein drugs, serious allergic reactions to the requested product, use of the multiple-dose vials containing benzyl alcohol in neonates, infants, pregnant women, and lactating women]
AND
3. (a) IF THIS IS A PHARMACY BENEFIT REQUEST FOR A NON-FORMULARY/NON-PREFERRED PRODUCT: Documentation of trial/failure of or serious side effects to a majority (not more than 3) of the preferred formulary/PDL alternatives for the given diagnosis. Documentation of medication(s) tried, dates of trial(s) and reason for treatment failure(s) is required.
AND
(b) If request is for reference product with a biosimilar available for initial or continuation of therapy requests: Documentation of a trial and failure, serious side effects or contraindication to a majority (not more than 3) biosimilar product(s) is required (unless otherwise specified per applicable state regulations and/or there is data demonstrating clinical superiority of reference drugs over the FDA approved biosimilar drugs).
[DOCUMENTATION REQUIRED: Document when the preferred biologic product or biosimilar was tried and the length of the trial period. Provide specific clinical documentation of therapeutic failure on the preferred biologic product or biosimilar whenever possible. Describe the medical problem caused by the preferred referenced biologic. Vague and non-descriptive symptoms are not adequate rationale (e.g., stomachache).]
OR
4. FOR INITIAL OR CONTINUATION OF THERAPY REQUESTS OF A PHYSICIAN ADMINISTERED MEDICATION: BIOSIMILAR DRUGS are preferred when requested as a physician administered drug per applicable state regulations and/or there is a lack of data demonstrating clinical superiority of reference drugs over the FDA approved biosimilar drugs. A reference medication is approved under the following conditions:
 - a. Treatment with at least two (2) associated biosimilar drug(s) has been ineffective, not tolerated, or is contraindicated (i.e. an allergic reaction to a specific inactive ingredient in the preferred biologic product or biosimilar OR an adverse reaction to a specific inactive ingredient in the preferred biologic product or biosimilar OR therapeutic success while taking a non-preferred biologic product or biosimilar and therapeutic failure while taking the preferred biologic product or biosimilar documented by patient diary or medical charted notes)
[DOCUMENTATION REQUIRED: Document when the preferred biologic product or biosimilar was tried and the length of the trial period. Provide specific clinical documentation of therapeutic failure on the preferred biologic product or biosimilar whenever possible. Describe the medical problem caused by the preferred referenced biologic. Vague and non-descriptive symptoms are not adequate rationale (e.g., stomachache).]
AND
5. CRITERIA BY INDICATION BELOW:

B. ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) INCLUDING MEMBERS ON DIALYSIS AND MEMBERS NOT ON DIALYSIS:

1. Documentation member has chronic kidney disease and/or is receiving dialysis
AND
2. Documentation hemoglobin (Hgb) level measured within last two weeks meets ONE of the following
[DOCUMENTATION REQUIRED]:

Drug and Biologic Coverage Criteria

- a. Treatment naïve: Hemoglobin <10 g/dL adults and < 11.0 g/dL for children OR
 - b. Currently receiving therapy: Hemoglobin < 11.5 g/dL for adults and <12 g/dL for children
AND
3. Any other causes of anemia (i.e., Iron deficiency, underlying infection, or inflammatory process, underlying hematological disease, hemolysis, vitamin deficiencies, blood loss, aluminum intoxication, drug exposure history, gastrointestinal bleeding) have been considered, documented, and corrected (when possible)
- C. ANEMIA DUE TO MYELOSUPPRESSIVE CHEMOTHERAPY FOR A NON-MYELOID MALIGNANCY:
1. Documented diagnosis of non-myeloid malignancy defined as any malignancy that is not a myeloid leukemia AND member is currently receiving chemotherapy
AND
 2. Member has minimum of two additional months of planned chemotherapy or is NOT within 8 weeks of the final chemotherapy dose
AND
 3. Documentation hemoglobin (Hgb) level measured within last two weeks < 10 g/dL
[DOCUMENTATION REQUIRED]
AND
 4. Other causes of anemia (i.e., Iron deficiency, underlying infection, or inflammatory process, underlying hematological disease, hemolysis, vitamin deficiencies, blood loss, aluminum intoxication, drug exposure history, gastrointestinal bleeding) have been considered, documented, and corrected (when possible)
- D. REDUCTION OF ALLOGENEIC BLOOD TRANSFUSION IN SURGERY:
1. Documentation member is undergoing elective, non-cardiac, non-vascular surgery
AND
 2. Documentation hemoglobin level within 30 days prior to scheduled surgery ≤ 13.0 g/dL
[DOCUMENTATION REQUIRED]
AND
 3. Prescriber attests to all of the following: Member is at high risk for perioperative transfusions with significant, anticipated blood loss AND Member is unable or unwilling to donate autologous blood AND Antithrombotic prophylaxis has been considered
AND
 4. Member has NOT received OR request is NOT for more than a 21-day supply or 15 doses for the surgery
- E. ANEMIA IN HIV-INFECTED MEMBER RECEIVING ZIDOVUDINE TREATMENT:
1. Documentation of HIV diagnosis
AND
 2. Member has been receiving zidovudine with a dose less than or equal to 4200mg per week
AND
 3. Documentation hemoglobin (Hgb) level measured within the last two weeks meets ONE of the following [DOCUMENTATION REQUIRED]:
 - a. Treatment naïve: Hemoglobin < 10g/dL OR
 - b. Currently receiving therapy: Hemoglobin < 12 g/dL
AND
 4. Documentation baseline endogenous erythropoietin lab level is less than or equal to 500mUnits/mL
AND
 5. Other causes of anemia (i.e., Iron deficiency, underlying infection, or inflammatory process, underlying hematological disease, hemolysis, vitamin deficiencies, blood loss, aluminum intoxication, drug exposure history, gastrointestinal bleeding) have been considered, documented and corrected (when possible)
- F. ANEMIA ASSOCIATED WITH MYELOYDYSPLASTIC SYNDROME:
1. Documented diagnosis of myelodysplastic syndrome

Drug and Biologic Coverage Criteria

AND

2. Documentation laboratory values meet ONE of the following [DOCUMENTATION REQUIRED]:
 - a. Hb is \leq 10 g/dL for initial therapy
 - OR
 - b. Serum erythropoietin level is \leq 500 mU/mL for initial therapy
 - OR
 - c. Hb is \leq 12.0 g/dL for members currently receiving Aranesp or epoetin alfa

AND

3. Other causes of anemia (i.e., Iron deficiency, underlying infection or inflammatory process, underlying hematological disease, hemolysis, vitamin deficiencies, blood loss, aluminum intoxication, drug exposure history, gastrointestinal bleeding) have been considered, documented and corrected (when possible)

G. ANEMIA OF PREMATURITY:

1. Documentation of anemia

AND

2. Documentation of member's gestational age at birth of 28 weeks or less [DOCUMENTATION REQUIRED]

AND

3. Documentation of member's birth weight of 1500 grams or less [DOCUMENTATION REQUIRED]

AND

4. Member is receiving concurrent iron and protein supplementation as required

CONTINUATION OF THERAPY:

- A. ALL INDICATIONS [ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) INCLUDING MEMBERS ON DIALYSIS AND MEMBERS NOT ON DIALYSIS, ANEMIA DUE TO MYELOSUPPRESSIVE CHEMOTHERAPY FOR A NON- MYELOID MALIGNANCY, ANEMIA IN HIV-INFECTED MEMBER RECEIVING ZIDOVUDINE TREATMENT, ANEMIA ASSOCIATED WITH MYELOYDYSPLASTIC SYNDROME]:

1. Documentation laboratory values meet ONE of the following [DOCUMENTATION REQUIRED]:
 - (a) NON-MYELOID MALIGNANCY: Recent hemoglobin (Hgb) level is less than 10 g/dL OR hematocrit is $<$ 30%
 - OR
 - (b) ALL OTHER INDICATIONS: Recent hemoglobin is $<$ 12g/dL
- AND
2. Documentation recent serum ferritin is $>$ 100 ng/mL or transferrin saturation $>$ 20% OR Member is receiving appropriate iron supplementation
- AND
3. Documentation of improvement in hematocrit and hemoglobin levels or there is a significant decrease in transfusion requirements
NOTE: For members not responding, despite dose titrations and/or concomitant use of G-CSF (e.g., filgrastim injection) during the first 6 months, discontinue epoetin alfa and evaluate and treat for other causes of anemia.
- AND
4. Prescriber attests to or clinical reviewer has found no evidence of intolerable adverse effects or drug toxicity

DURATION OF APPROVAL:

For Reduction of Allogeneic Blood Transfusion in Surgery: Initial authorization: Up to 21 days of therapy per surgery, or up to 15 doses, Continuation of Therapy: N/A

Anemia of Prematurity: Initial authorization: 2 months (8 weeks), Continuation of Therapy: N/A

All other indications: Initial authorization: 2 months (8 weeks), Continuation of Therapy: 6 months (24 weeks)

PRESCRIBER REQUIREMENTS:

Prescribed by or in consultation with a board-certified hematologist, oncologist, nephrologist,

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

immunologist, surgeon, infectious disease specialist, or neonatologist (for anemia of prematurity). [If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests]

AGE RESTRICTIONS:

Anemia associated with chronic kidney disease (CKD) in an individual on dialysis:

Epogen/Procrit/Retacrit/Aranesp: 1 month of age and older

Mircera: 3 months of age and older

Anemia associated with chronic kidney disease (CKD) in an individual NOT on dialysis:

Epogen/Procrit/Retacrit/Aranesp: 1 month of age and older

Mircera: 3 months of age and older

Anemia due to myelosuppressive chemotherapy for a non-myeloid malignancy:

Epogen/Procrit/Retacrit: 5 years of age and older

Aranesp: 18 years of age and older

Reduction of allogeneic blood transfusion requirements in surgery:

Epogen/Procrit/Retacrit: 18 years of age and older

Anemia due to zidovudine in HIV-infected patients:

Epogen/Procrit/Retacrit: 8 months of age and older

Anemia associated with myelodysplastic syndrome:

Epogen/Procrit/Retacrit: 18 years of age and older

Aranesp: 18 years of age and older

Anemia of prematurity:

Epogen/Procrit/Retacrit/Aranesp: no restriction

QUANTITY:

Dosage, frequency, and total treatment duration must be supported by FDA label or compendia supported dosing for prescribed indication

Epoetin alfa and biosimilars: Not to exceed 3 doses weekly

Darbepoetin alfa: Not to exceed 4 doses monthly

Mircera: Adults not to exceed one dose every 2 weeks maximum. Pediatric ages 3 months to 17 years of age not to exceed one dose every 4 weeks.

Single-dose vials and syringes are available in many different strengths. The dose should be calculated, and the number of vials/syringes needed assessed. Refer to the corresponding package insert for more information.

PLACE OF ADMINISTRATION:

The recommendation is that injectable medications in this policy will be for pharmacy or medical benefit coverage and the subcutaneous injectable products be administered in a place of service that is a non-hospital facility-based location.

The recommendation is that infused medications in this policy will be for pharmacy or medical benefit coverage administered in a place of service that is a non-inpatient hospital facility-based location.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Intravenous or subcutaneous

Drug and Biologic Coverage Criteria

DRUG CLASS:

Erythropoiesis-stimulating agents (ESAs)

FDA-APPROVED USES:

EPOETIN ALFA:

Indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.

Indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg per week in HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.

Indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dl who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. It is not indicated for patients who are willing to donate autologous blood pre-operatively.

Limitations of Use: Procrit/Retacrit/Epogen has not been shown to improve quality of life, fatigue, or patient well-being. Procrit/Retacrit/Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.

DARBEPOETIN ALFA:

Indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy.

Limitations of Use: Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. As a substitute for RBC transfusions in patients who require immediate correction of anemia.

METHOXY POLYETHYLENE GLYCOL-EPOETIN-BETA:

Indicated for the treatment of anemia associated with chronic kidney disease (CKD) in: adult patients on dialysis and adult patients not on dialysis and pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA.

Limitations of Use: Mircera is not indicated and is not recommended: In the treatment of anemia due to cancer chemotherapy. As a substitute for RBC transfusions in patients who require immediate correction of anemia. Mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life.

COMPENDIAL APPROVED OFF-LABELED USES:

Anemia Associated with Myelodysplastic Syndrome (MDS), Anemia of prematurity

APPENDIX

APPENDIX:

None

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

Anemia of prematurity-

The pathogenetic importance of impaired EPO production in AOP provides the rationale for the therapy with erythropoiesis stimulating agents (ESAs) including recombinant EPO. However, the administration of EPO has not been accepted widely because it appears to have limited efficacy in decreasing the number of blood donors to which the infant is exposed via transfusion, whether EPO is administered early (within the first week of life) or late (at or after eight days of life).

Although early administration (within the first eight days of life) of EPO reduces the number of transfusions required in preterm infants, (12) the small reduction may be of limited clinical importance, because EPO does not decrease the number of donor exposures due to the use of satellite packs.

These findings were best illustrated in a systematic review and meta-analysis of trials in preterm infants that evaluated the effect of early administration of EPO (given before eight days of age) compared with placebo or no intervention [38]. Many of these infants had received blood transfusions prior to enrollment in the trials. The following findings were noted: EPO reduced the risk of receiving one or more red blood cell transfusions (RR 0.79, 95% CI 0.74-0.85), the number of donors to whom transfused infants were exposed to was not reduced, mortality was similar for the EPO and placebo groups, similar risk of developing ROP stage ≥ 3 for both the EPO and placebo groups (relative risk [RR] 1.24, 95% CI 0.81-1.90). Infants in the EPO group had a lower risk of developing necrotizing enterocolitis (RR 0.69, 95% CI 0.52-91), neurodevelopmental impairment at 18 to 22 months postmenstrual age (PMA), intraventricular hemorrhage, and periventricular leukomalacia. (10) However, in a subsequent multicenter trial of 941 EPT infants studying the neuroprotective effects of EPO given within the first 24 hours after delivery, EPO compared with placebo had similar rates of the primary outcome of death or severe neurodevelopmental outcome at 22 to 26 months PMA (26 versus 26 percent; RR 1.03, [95% CI 0.81 to 1.32]). The groups also had similar rates of retinopathy of prematurity, intracranial hemorrhage, BPD, necrotizing enterocolitis, death or frequency of serious adverse effects (13)

Late administration of EPO reduces the number of transfusions, but the limited benefit does not justify its use. This was illustrated in a meta-analysis that evaluated the effects of late EPO administration (between eight and 28 days after birth) compared with placebo or no intervention [40]. Most of these infants had received blood transfusions prior to enrollment in the trials. The following findings were noted: EPO reduced the risk of receiving one or more red blood cell transfusions (RR 0.72, 95% CI 0.65-0.79), EPO reduced the number of red blood cell transfusions (weighted mean difference of -0.22, 95% CI -0.38 to -0.06), There was no difference in the volume of blood transfused (mean difference -1.6 mL/kg, 95% CI -5.8 to 2.6) and Late EPO use had no effect on the rates for mortality, sepsis and necrotizing enterocolitis (NEC). However, there was a trend towards an increased risk of ROP associated with EPO administration (RR 1.27, 95% CI 0.99-1.64).

Late administration of EPO reduced the mean number of transfusions by a little less than one transfusion per infant. This small benefit of EPO was diminished due to the exposure of previous blood transfusions before eight days of life, and the use of satellite packs that would mitigate against additional donor exposure in the control group.

NOTE: For the purposes of this policy, a conversion factor of 3 should be used to estimate hemoglobin when only the hematocrit (Hct) is measured, e.g., hemoglobin of 10 g/dL is approximately equal to a hematocrit of 30%, a hemoglobin of 11 g/dL is approximately equal to a hematocrit of 33%, and a hemoglobin of 12 g/dL is approximately equal to a hematocrit of 36%

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of erythropoiesis-stimulating agents (ESAs) are considered experimental/investigational and therefore, will follow Molina's Off- Label policy. Contraindications to erythropoiesis-stimulating agents

Drug and Biologic Coverage Criteria

(ESAs) include: uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with erythropoietin protein drugs, serious allergic reactions to the requested product, use of the multiple-dose vials containing benzyl alcohol in neonates, infants, pregnant women, and lactating women.

Exclusions/Discontinuation:

CONDITIONS NOT RECOMMENDED FOR APPROVAL Epoetin alfa has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

- Anemia Associated with Cancer in Members not Receiving Myelosuppressive Cancer Chemotherapy.** Epoetin alfa is not indicated in cancer members who are not receiving cancer chemotherapy.1-3 The American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) guidelines for the use of epoetin alfa and Aranesp in adult members with cancer recommend that ESAs not be used in treatment of anemia associated with malignancy in those who are not receiving concurrent myelosuppressive chemotherapy.6
- Anemia Associated with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML) or other Myeloid Cancers.** Epoetin alfa is indicated for use in non- myeloid cancers. AML and CML are examples of myeloid cancers.1-3
- Anemia Associated with Radiotherapy in Cancer.** Epoetin alfa is not indicated for use in members with cancer who are only given radiation therapy.1-3
- To Enhance Athletic Performance.** Epoetin alfa is not recommended for approval because this indication is excluded from coverage in a typical pharmacy benefit.
- Anemia in Members due to Acute Blood Loss.** Use of epoetin alfa is not appropriate in these types of situations.
- Non-Anemic Members (Hemoglobin [Hgb] > 13.0 g/dL) prior to Surgery.** Although studies have been done that involved non-anemic members undergoing various surgeries receiving epoetin alfa preoperatively and sometimes postoperatively to prevent transfusions or subsequent anemia, the overall benefit of this therapy in those with relatively normal preoperative Hb level is questionable. Any indication noted in the FDA label as “not indicated for use”.

OTHER SPECIAL CONSIDERATIONS:

Black Boxed warning: Erythropoiesis-stimulating agents (ESAs) increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence.

In pregnant women, lactating women, neonates, and infants use only single-dose vials (the benzyl alcohol-free formulation).

CODING/BILLING INFORMATION

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive or applicable for every state or line of business. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry-standard coding practices for all submissions. Molina has the right to reject/deny the claim and recover claim payment(s) if it is determined it is not billed appropriately or not a covered benefit. Molina reserves the right to revise this policy as needed.

HCPCS CODE	DESCRIPTION
------------	-------------

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units
J0888	Injection, epoetin beta, 1 microgram, (for non-esrd use)
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
J0882	Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)
J0887	Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
Q4081	Injection, epoetin alfa, 100 units (for esrd on dialysis)
Q5105	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units

AVAILABLE DOSAGE FORMS:

Aranesp (Albumin Free) SOLN 25MCG/ML, 40MCG/ML, 60MCG/ML, 100MCG/ML, 200MCG/ML single-dose vials

Aranesp (Albumin Free) SOSY 10MCG/0.4ML, 25MCG/0.42ML, 40MCG/0.4ML, 60MCG/0.3ML, 100MCG/0.5ML, 150MCG/0.3ML, 200MCG/0.4ML, 300MCG/0.6ML, 500MCG/ML single-dose prefilled syringes

Epogen SOLN 2000UNIT/ML, 3000UNIT/ML, 4000UNIT/ML, 10000UNIT/ML single-dose vials

Epogen SOLN 10000UNIT/ML, 20000UNIT/ML multiple-dose vials containing benzyl alcohol

Mircera SOSY 30MCG/0.3ML, 50MCG/0.3ML, 75MCG/0.3ML, 100MCG/0.3ML, 120MCG/0.3ML, 150MCG/0.3ML, 200MCG/0.3ML single-dose prefilled syringes

Procrit SOLN 2000UNIT/ML, 3000UNIT/ML, 4000UNIT/ML, 10000UNIT/ML, 40000UNIT/ML single-dose vials

Procrit SOLN 10000UNIT/ML, 20000UNIT/ML multiple-dose vials containing benzyl alcohol

Retacrit SOLN 2000UNIT/ML, 3000UNIT/ML, 4000UNIT/ML, 10000UNIT/ML, 40000UNIT/ML single-dose vials

Retacrit SOLN 10000UNIT/ML, 20000UNIT/ML multiple-dose vials containing benzyl alcohol

REFERENCES

1. Aranesp (darbepoetin alfa) injection, for intravenous or subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2024.
2. Epogen (epoetin alfa) injection, for intravenous or subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2024.
3. Mircera (methoxy polyethylene glycol-epoetin beta) injection, for intravenous or subcutaneous use [prescribing information]. Switzerland: Vifor (International) Inc.; June 2024.
4. Procrit (epoetin alfa) injection, for intravenous or subcutaneous use [prescribing information]. Horsham, PA: Janssen Products, LP; April 2024.
5. Retacrit (epoetin alfa-epbx) injection, for intravenous or subcutaneous use [prescribing information]. New York, NY and Lake Forest, IL: Pfizer and Hospira; June 2024.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Inter.* 2012;2(Suppl):279-335. Available at: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGOAnemia%20GL.pdf. Accessed on June 18, 2018.
7. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for members with AIDS treated with zidovudine. *N Engl J Med.* 1990;322:1488-1493.
8. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the use of epoetin and darbepoetin in adult members with cancer. *J Clin Oncol.* 2010;28(33):4996-5010.
9. National Comprehensive Cancer Network. 2022. Hematopoietic Growth Factors (Version 1.2022). [online] Available at: < growthfactors.pdf (nccn.org)> [Accessed 30 June 2022]

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

10. Afdhal NH, Dieterich DT, Pockros PJ, et al: Epoetin alfa maintains ribavirin dose in HCV-infected members: a prospective, double-blind, randomized controlled study. *Gastroenterology* 2004; 126(5):1302-1311.
11. Silverberg D, Wexler D, Blum M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. *J Am Coll Cardiol* 2000; 35(7):1737-1744.
12. Komai H, Naito Y, Iwasaki Y, et al: Autologous blood donation with recombinant human erythropoietin for abdominal aortic aneurysm surgery. *Surg Today* 2000;30:511-515
13. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. *Cochrane Database Syst Rev.* 2020 Feb 11;2(2):CD004863. doi: 10.1002/14651858.CD004863.pub6. PMID: 32048730; PMCID: PMC7014351.
14. Aher SM, Ohlsson A. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. *Cochrane Database Syst Rev.* 2020 Jan 28;1(1):CD004868. doi: 10.1002/14651858.CD004868.pub6. PMID: 31990982; PMCID: PMC6986694.
15. Maier R, Obladen M, Scigalla P, et al. The effect of epoietin beta (recombinant human erythropoietin) on the need for transfusion in very low birth weight infants. *N Engl J Med.* 1994; 330:1173.
16. Juul SE, Comstock BA, Wadhawan R, et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. *N Engl J Med* 2020; 382:233
17. Vamvakas EC, Strauss RG: Meta-analysis of controlled clinical trials studying the efficacy of recombinant human erythropoietin in reducing blood transfusions in the anemia of prematurity. *Transfusion* 41:406-415, 2001
18. Shannon KM, Keith JF III, Mentzer WC, et al: Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very-low-birth-weight preterm infants. *Pediatrics* 95:1-8, 1995
19. Kumar P, Shankaran S, Krishnan RO: Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very-low-birth-weight infants: A randomized, doubleblind, placebo- controlled trial. *J Perinatol* 18:173-177, 1998
20. Bohlius, J., Bohlke, K., Castelli, R., Djulbegovic, B., Lustberg, M. B., Martino, M., ... Lazo- Langner, A. (2019). Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. *Journal of Clinical Oncology*, 37(15), 1336–1351. <https://doi.org/10.1200/jco.18.02142>
21. National Comprehensive Cancer Network. 2023. Hematopoietic Growth Factors (Version 2.2023). [online] Available at: < [growthfactors.pdf \(nccn.org\)](#) > [Accessed 13 June 2023].
22. National Comprehensive Cancer Network. 2024. Hematopoietic Growth Factors (Version 3.2024). [online] Available at: < [growthfactors.pdf \(nccn.org\)](#) > [Accessed 12 July 2024].
23. National Comprehensive Cancer Network. 2025. Hematopoietic Growth Factors (Version 1.2025). [online] Available at: < [growthfactors.pdf \(nccn.org\)](#) > [Accessed 26 June 2025].

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: Diagnosis Required Medical Information Continuation of Therapy Age Restrictions Appendix Contraindications/Exclusions/Disc ontinuation References	Q3 2025

Drug and Biologic Coverage Criteria

REVISION- Notable revisions: Age Restrictions Quantity FDA-Approved Uses Available Dosage Forms References	Q3 2024
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Age Restrictions FDA-Approved Uses Contraindications/Exclusions/Discontinuation Other Special Considerations Coding/Billing Information References	Q3 2023
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Duration of Approval Prescriber Requirements References	Q3 2022
Q2 2022 Established tracking in new format	Historical changes on file